EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY-NC-ND 4.0

The effect of severe renal impairment on the pharmacokinetics, safety and tolerability of balcinrenone

Chandrali S Bhattacharya, Hans Ericsson iD, Susanne Johansson iD, Joanna Parkinson iD, Simina M Boca, Ye Yang, Maria Heijer, Greggory Housler, Maria Leonsson-Zachrisson, Judith Hartleib-Geschwindner, Patricia Ely Pizzato

British Journal of Clinical Pharmacology · 2025-07 · 91 (7) · 1937-1946

DOI: 10.1002/bcp.70017 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 17.02.2025. Verfasst von Chandrali S Bhattacharya und 10 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD…. Hauptthemen laut MEDLINE: Renal Insufficiency, Mineralocorticoid Receptor Antagonists. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The aim of this phase 1 trial was to assess the pharmacokinetics, safety and tolerability of balcinrenone (previously AZD9977) in participants with severe renal impairment vs . those with normal renal function.

Methods

Participants with severe renal impairment (estimated glomerular filtration rate [eGFR] < 30 mL/min/1.73 m 2 ) not on dialysis were compared with group‐matched control participants with eGFR ≥ 90 mL/min/1.73 m 2 . Eligible participants received a single oral dose of 150 mg balcinrenone, and blood and urine samples were collected for analysis.

Results

The total apparent balcinrenone clearance was 50% lower in the severe renal impairment group, resulting in an approximately two‐fold higher area under the curve (AUC) and a 1.4‐fold higher maximum observed plasma concentration in the severe renal impairment group compared with the control group. The terminal half‐life and plasma protein binding were similar in both groups. Balcinrenone was safe and well tolerated in all participants. All reported adverse events were of mild‐to‐moderate severity and not considered related to balcinrenone.

Conclusions

Balcinrenone exposure was approximately two‐fold higher in participants with severe renal impairment compared with the group‐matched control participants. Based on linear regression analysis of total apparent balcinrenone clearance vs . baseline eGFR, the AUC exposure is predicted to be

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Renal InsufficiencyMineralocorticoid Receptor AntagonistsHumansMaleFemaleMiddle AgedGlomerular Filtration RateAdultAgedArea Under CurveSeverity of Illness IndexHalf-LifeAdministration, Oral

Stichwörter der Autor:innen

chronic kidney diseasedrug safetyheart failurepharmacokineticsphase I

Substanzen

Mineralocorticoid Receptor Antagonists

Autor:innen und Institutionen

  • Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
  • Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Early Biometrics & Statistical Innovation, Data Science & Artificial Intelligence, R&D, AstraZeneca, Gaithersburg, MD, USA.
  • Integrated Bioanalysis, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
  • Early Clinical Development, Research and Early Clinical Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
  • Late-stage Clinical Development, Cardiovascular, Renal and Metabolic, AstraZeneca BioPharmaceuticals R&D, Gothenburg, Sweden.

ORCID-Profile: Hans Ericsson, Susanne Johansson, Joanna Parkinson

Förderung

  • AstraZeneca

Zitieren

APA

Bhattacharya, C. S., Ericsson, H., Johansson, S., Parkinson, J., Boca, S. M., Yang, Y., Heijer, M., Housler, G., Leonsson-Zachrisson, M., Hartleib-Geschwindner, J., & Pizzato, P. E. (2025). The effect of severe renal impairment on the pharmacokinetics, safety and tolerability of balcinrenone. British Journal of Clinical Pharmacology, 91(7), 1937-1946. https://doi.org/10.1002/bcp.70017

Vancouver

Bhattacharya CS, Ericsson H, Johansson S, Parkinson J, Boca SM, Yang Y, et al. The effect of severe renal impairment on the pharmacokinetics, safety and tolerability of balcinrenone. British Journal of Clinical Pharmacology. 2025;91(7):1937-1946. doi:10.1002/bcp.70017

BibTeX
@article{Bhattacharya2025,
  author = {Bhattacharya, Chandrali S and Ericsson, Hans and Johansson, Susanne and Parkinson, Joanna and Boca, Simina M and Yang, Ye and Heijer, Maria and Housler, Greggory and Leonsson-Zachrisson, Maria and Hartleib-Geschwindner, Judith and Pizzato, Patricia Ely},
  title = {The effect of severe renal impairment on the pharmacokinetics, safety and tolerability of balcinrenone},
  journal = {British Journal of Clinical Pharmacology},
  year = {2025},
  volume = {91},
  number = {7},
  pages = {1937--1946},
  doi = {10.1002/bcp.70017}
}
Kostenlos starten →